The emergence of antibody therapies for Ebola

Andrew Hiatt, Michael Pauly, Kevin Whaley, Xiangguo Qiu, Gary Kobinger, Larry Zeitlin

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations

Abstract

This review describes the history of Ebola monoclonal antibody (mAb) development leading up to the recent severe Ebola outbreak in West Africa. The Ebola virus has presented numerous perplexing challenges in the long effort to develop therapeutic antibody strategies. Since the first report of a neutralizing human anti-Ebola mAb in 1999, the straightforward progression from in vitro neutralization resulting in in vivo protection and therapy has not occurred. A number of mAbs, including the first reported, failed to protect non-human primates (NHPs) in spite of protection in rodents. An appreciation of the role of effector functions to antibody efficacy has contributed significantly to understanding mechanisms of in vivo protection. However a crucial contribution, as measured by post-exposure therapy of NHPs, involved the comprehensive testing of mAb cocktails. This effort was aided by the use of plant production technology where various combinations of mAbs could be rapidly produced and tested. Introduction of appropriate modifications, such as specific glycan profiles, also improved therapeutic efficacy. The resulting cocktail, ZMapp™, consists of three mAbs that were identified from numerous mAb candidates. ZMapp™ \ is now being evaluated in human clinical trials but has already played a role in bringing awareness to the potential of antibody therapy for Ebola.

Original languageEnglish (US)
Pages (from-to)49-56
Number of pages8
JournalHuman Antibodies
Volume23
Issue number3-4
DOIs
StatePublished - Dec 23 2015
Externally publishedYes

Keywords

  • Ebola antibody discovery
  • Ebola virus
  • effector functions
  • passive immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'The emergence of antibody therapies for Ebola'. Together they form a unique fingerprint.

Cite this